trial · primary record
Pembrolizumab
Breast Cancer
| Phase | Phase 2 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 14 |
| Primary completion | 2025-11-21 |
| Primary endpoint | Overall Response Rate (ORR) Per RECIST1.1 |
| Registry ID | NCT03025035 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:38:04.074Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03025035
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- PEMBROLIZUMAB · approval
- Pembrolizumab · compound